slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 46,291-46,320
Pages 3,679
Rows per page 30
Component
46,291-46,320 of 110,355
140
The slide uses a quote from a consultant to challenge the validity of the company's (Harmony) data submitted to the FDA.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
141
The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
142
The slide uses direct excerpts from regulatory documents to challenge the company's claims regarding drug safety and pharmacokinetics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
144
The slide uses a Wikipedia table to demonstrate the complexity of CYP2D6 phenotypes to undermine the validity of the FDA's small-sample study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
146
The slide uses a 'red flag' narrative to challenge the integrity of clinical trial data reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
147
The slide uses direct excerpts from FDA documents and product labels to highlight a contradiction in clinical trial methodology.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
148
The slide uses a combination of narrative argument and a supporting data table to challenge the safety profile of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
149
The slide uses regulatory documents (EMA/FDA) and primary research (prescriber interviews) to build a case for potential safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
150
The slide uses a specific calculation (153 ng/mL * 4 * 2 = 1224 ng/mL) to quantify risk.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
151
Uses anecdotal evidence from Facebook patient support groups to highlight a safety gap.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
152
The slide uses red underlining to highlight specific dangerous medical advice given to patients.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
154
The slide uses a 'villain critique' style to frame the FDA's approval as flawed and the drug's safety as compromised.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
156
The slide uses a combination of narrative analysis and a specific case study excerpt to challenge the safety profile of pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
157
The slide presents clinical case summaries to address potential safety concerns regarding cardiac events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
158
The slide uses direct quotes from FDA clinical reviews to highlight the discrepancy between pre-approval assumptions and post-approval safety signals.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
160
The slide highlights the FDA's 'wait-and-see' posture and specific concerns about seizures as a safety signal for the drug pitolisant.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
161
The slide uses a 'fraud-exposure' or 'investigative' tone to question the lack of public data on a specific study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
163
The slide uses a 'villain' narrative to frame the company's non-disclosure as intentional concealment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
164
The slide uses a combination of original analysis and cited medical literature to challenge the transparency of clinical trial reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
165
The slide uses a 'preempt_rebuttal' strategy by highlighting a specific safety concern (eosinophilic abnormality) that the authors claim was ignored in official FDA review documents.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
166
The slide uses a scientific table to challenge the 'no appreciable binding' claim found in a drug's package insert, citing reproducibility concerns regarding the source of that claim.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses specific case descriptions to argue for a pattern of respiratory/pulmonary-related deaths.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a specific medical case study to establish a pattern of misdiagnosis and severity, linking it to the current subject (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit